Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-c immunoglobulin is a polyclonal antibody preparation used for the treatment of immune thrombocytopenic purpura (ITP), particularly in patients who are Rh-negative but c-positive. It consists of IgG antibodies directed against the c antigen of the Rh blood group system. When administered, these antibodies bind to the patient's red blood cells, which are then cleared by the spleen's macrophages. This clearance process saturates the Fc receptors on the macrophages, preventing them from destroying the patient's autoantibody-coated platelets, thereby raising the platelet count. This mechanism is known as Fc receptor blockade. While anti-D (Rho(D) immune globulin) is more commonly used for Rh-positive patients, anti-c provides a therapeutic option for Rh-negative individuals who possess the c antigen.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on anti-c immunoglobulin.